Due diligence frameworks and strategic intelligence for evaluating CGT assets
A 12 question vector rights self-assessment and six steps to prepare a decision record with your IP/patent counsel.
Why RMAT and BTD status are no longer the de-risking signals investors thought. The Plausible Mechanism Pathway changes how you evaluate gene therapy assets.
Our expert consultants are ready to help you evaluate your pipeline and develop winning investment strategies.
Book a Free Discovery Call